SOURCE: Paragon Financial Limited

Paragon Financial Limited

December 01, 2011 08:16 ET

Antares Pharma and Radient Pharmaceuticals See Uptick in Demand

The Paragon Report Provides Equity Research on Antares Pharma & Radient Pharmaceuticals

NEW YORK, NY--(Marketwire - Dec 1, 2011) - The global market for Medical Equipment and Supplies is expected to grow rapidly in the coming years. Companies in the sector are seeing expansion in emerging markets where booming economies have opened up new opportunities for medical device makers. The Paragon Report examines investing opportunities in the Medical Equipment & Supplies industry and provides equity research on Antares Pharma, Inc. (NYSE Amex: AIS) and Radient Pharmaceuticals Corporation (PINKSHEETS: RXPC). Access to the full company reports can be found at:

According to BCC Research, estimated global demand for minimally invasive surgical instruments (including stents, catheters, balloons and other devices used in angioplasty) was worth an estimated $13.4 billion in 2010 is estimated to hit $23 billion by 2014. Orthopedic surgery is the fastest growing application segment, with an estimated growth rate of 11.2% between 2011 and 2016, followed by cardiothoracic surgery (8%) and vascular surgery (7.8%).

BCC research also finds that the US market for medical robotics and computer-assisted surgical equipment was worth an estimated $648 million in 2008. The market is projected to reach $1.5 billion by 2014.

The Paragon Report provides investors with an excellent first step in their due diligence by providing daily trading ideas, and consolidating the public information available on them. For more investment research on theMedical Equipment & Supplies industry register with us free at and get exclusive access to our numerous stock reports and industry newsletters.

Antares Pharma focuses on self-injection pharmaceutical products and technologies, and topical gel-based products. The company is developing LibiGel in partnership with BioSante to treat female sexual dysfunction, specifically hypoactive sexual desire disorder, in postmenopausal women, for which there is no Food and Drug Administration-approved product. Shares of the company got a boost last month after it said a study shows its LibiGel increased free-testosterone levels in postmenopausal women.

Radient Pharmaceuticals offers ONKO-SURE, a proprietary in-vitro diagnostic cancer test, which is used for the detection and/or monitoring of lung, breast, stomach, liver, colon, rectal, ovarian, esophageal, cervical, trophoblastic, thyroid, malignant lymphoma, and pancreatic cancers. Shares of the company skyrocketed earlier this week after it announced it completed restructurings with each of the company's 2011 Noteholders and Alpha Capital Anstalt and Whalehaven Capital Fund Ltd. Radient Chairman and CEO, Mr. Douglas MacLellan says the restructuring "alleviates an immediate financial burden on Radient and allows Radient to focus on gaining traction on its sales of Onko-Sure domestically and internationally."

The Paragon Report has not been compensated by any of the above-mentioned publicly traded companies. Paragon Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at